Dr. Tobias Silzle
Medizinische Onkologie und Hämatologie · Dept. I
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickelberghe V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2023; 390:301-313.
Dec 12, 2023Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dec 12, 2023N Engl J Med 2023; 390:301-313
Sonneveld Pieter, Dimopoulos Meletios A, Boccadoro Mario, Quach Hang, Ho P Joy, Beksac Meral, Hulin Cyrille, Antonioli Elisabetta, Leleu Xavier, Mangiacavalli Silvia, Perrot Aurore, Cavo Michele, Belotti Angelo, Broijl Annemiek, Gay Francesca, Mina Roberto, Nijhof Inger, van de Donk Niels W C J, Katodritou Eirini, Schjesvold Fredrik, Sureda Balari Anna, Rosiñol Laura, Delforge Michel, Roeloffzen Wilfried, Silzle Tobias, Vangsted Annette Juul, Einsele Hermann, Spencer Andrew, Hájek Roman, Jurczyszyn Artur, Lonergan Sarah, Ahmadi Tahamtan, Liu Yanfang, Wang Jianping, Vieyra Diego, van Brummelen Emilie M J, Vanquickelberghe Veronique, Sitthi-Amorn Anna, Van de Velde Cornelis J H, Carson Robin, Rodriguez-Otero Paula, Bladé Joan, Moreau Philippe, PERSEUS Trial Investigators
Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study.
Koster K, Messerich N, Volken T, Cogliatti S, Lehmann T, Graf L, Holbro A, Benz R, Demmer I, Jochum W, Rao T, Silzle T. Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study. Cancers (Basel) 2023; 15
Sep 24, 2023Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study.
Sep 24, 2023Cancers (Basel) 2023; 15
Koster Kira-Lee, Messerich Nora-Medea, Volken Thomas, Cogliatti Sergio B., Lehmann Thomas, Graf Lukas, Holbro Andreas, Benz Rudolf, Demmer Izadora, Jochum Wolfram, Rao Tata Nageswara, Silzle Tobias
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Silzle T, Blum S, Kasprzak A, Nachtkamp K, Rudelius M, Hildebrandt B, Götze K, Gattermann N, Lauseker M, Germing U. The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score. Cancers (Basel) 2023; 15
Jul 11, 2023The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Jul 11, 2023Cancers (Basel) 2023; 15
Silzle Tobias, Blum Sabine, Kasprzak Annika, Nachtkamp Kathrin, Rudelius Martina, Hildebrandt Barbara, Götze Katharina S, Gattermann Norbert, Lauseker Michael, Germing Ulrich
Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. Swiss Med Wkly 2023; 153:40090.
Jun 15, 2023Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Jun 15, 2023Swiss Med Wkly 2023; 153:40090
Silzle Tobias, Kahlert Christian, Albrich Werner, Nigg Susanne, Demmer-Steingruber Ruth, Driessen Christoph, Fischer Stefanie
A spiky issue.
Silzle T, Appenzeller C. A spiky issue. Blood 2023; 141:1646.
Mar 30, 2023A spiky issue.
Mar 30, 2023Blood 2023; 141:1646
Silzle Tobias, Appenzeller Christina
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
Messerich N, Uda N, Volken T, Cogliatti S, Lehmann T, Holbro A, Benz R, Graf L, Gupta V, Jochum W, Demmer I, Rao T, Silzle T. CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study. Cancers (Basel) 2023; 15
Feb 25, 2023CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
Feb 25, 2023Cancers (Basel) 2023; 15
Messerich Nora-Medea, Uda Narasimha Rao, Volken Thomas, Cogliatti Sergio B., Lehmann Thomas, Holbro Andreas, Benz Rudolf, Graf Lukas, Gupta Vikas, Jochum Wolfram, Demmer Izadora, Rao Tata Nageswara, Silzle Tobias
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E, Fischer K, R Demmer-Steingruber, Nigg S, Güsewell S, Albrich W, Rothermundt C, Silzle T, Kahlert C. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open 2022; 7:100587.
Aug 24, 2022Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Aug 24, 2022ESMO Open 2022; 7:100587
Su E, Fischer Katharina S, R Demmer-Steingruber, Nigg Susanne, Güsewell Sabine, Albrich Werner, Rothermundt Christian, Silzle Tobias, Kahlert Christian
[How Myelodysplastic Syndrome is Diagnosed].
Silzle T. [How Myelodysplastic Syndrome is Diagnosed]. Ther Umsch 2022; 78:77-85.
Jan 1, 2022[How Myelodysplastic Syndrome is Diagnosed].
Jan 1, 2022Ther Umsch 2022; 78:77-85
Silzle Tobias
A case of reactive hemophagocytic lymphohistiocytosis
Lorenz L, Silzle T, Brühl D, Haller S, Babouee Flury B (2021). A case of reactive hemophagocytic lymphohistiocytosis - The value of asking the right questions at the right time.
May 19, 2021A case of reactive hemophagocytic lymphohistiocytosis
May 19, 2021SGAIM Frühjahrskongress
Lorenz Lisa, Silzle Tobias, Brühl Daniel, Haller Sabine, Babouee Flury Baharak
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 2021; 5:1110-1121.
Jan 23, 2021Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Jan 23, 2021Blood Adv 2021; 5:1110-1121
Ossenkoppele Gert J, Porkka Kimmo, Cornelissen Jan, Kuball Juergen, Fischer Thomas, Legdeur Marie-Cecile J C, Hoogendoorn Mels, Breems Dimitri A, Moors Ine, van Lammeren-Venema Daniëlle, Silzle Tobias, Juliusson Gunnar, Meyer Peter, Floisand Yngvar, Manz Markus G, van Elssen Catharina H M J, Valk Peter J M, Cloos Jacqueline, Passweg Jakob, Huls Gerwin, Janssen Jeroen J W M, Gjertsen Bjorn T, Höglund Martin, Gregor Michael, Veelken Hendrik, van Marwijk Kooy Marinus, Jongen-Lavrencic Mojca, Tick Lidwine W, Griskevicius Laimonas, Vellenga Edo, Spertini Olivier, Biemond Bart J, Gradowska Patrycja, Maertens Johan, Pabst Thomas, Vekemans Marie-Christiane, van der Velden Walter J F M, Westerweel Peter E, Gadisseur Alain, Klein Saskia K, Bargetzi Mario, van Esser Joost W J, de Weerdt Okke, Deeren Dries, Graux Carlos, Michaux Lucienne, Beverloo Berna, Löwenberg Bob
Guideline-based indicators for adult patients with myelodysplastic syndromes
Silzle T. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances 2020; 4:4029-4044.
Dec 13, 2020Guideline-based indicators for adult patients with myelodysplastic syndromes
Dec 13, 2020Blood Advances 2020; 4:4029-4044
Silzle Tobias
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
Aug 27, 2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Aug 27, 2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
Silzle T, Blum S, Schuler E, Kaivers J, Rudelius M, Hildebrandt B, Gattermann N, Haas R, Germing U. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer J 2019; 9:63.
Aug 9, 2019Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients
Aug 9, 2019Blood Cancer J 2019; 9:63
Silzle Tobias, Blum Sabine, Schuler Esther, Kaivers Jennifer, Rudelius Martina, Hildebrandt Barbara, Gattermann Norbert, Haas Rainer, Germing Ulrich
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
Nov 21, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Nov 21, 2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Jul 28, 2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Jul 28, 2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
Jun 11, 2015The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Jun 11, 2015Haematologica 2015; 100:1350-60
Kraus Marianne, Overkleeft Herman, Kisselev Alexei F, Li Nan, Appenzeller Christina, van Rooden Eva, Haile Sarah, de Bruin Gerjan, van der Linden Wouter A, Shabaneh Tamer B, Silzle Tobias, Mirabella Anne C, Weyburne Emily S, Geurink Paul P, Bader Juergen, Driessen Christoph
A hairy issue
Silzle T, Hitz F. A hairy issue. Blood 2014; 123:958.
Feb 13, 2014A hairy issue
Feb 13, 2014Blood 2014; 123:958
Silzle Tobias, Hitz Felicitas
Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis
Daskalakis M, Colucci G, Keller P, Rochat S, Silzle T, Biasiutti F, Barizzi G, Alberio L. Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry B Clin Cytom 2014; 86:397-409.
Feb 12, 2014Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis
Feb 12, 2014Cytometry B Clin Cytom 2014; 86:397-409
Daskalakis Michael, Colucci Giuseppe, Keller Peter, Rochat Sophie, Silzle Tobias, Biasiutti Franziska Demarmels, Barizzi Gabriela, Alberio Lorenzo
Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia
Silzle T, Glaser-Gallion N, Hitz F. Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia. Eur J Haematol 2013; 92:90.
Sep 17, 2013Posterior reversible encephalopathy syndrome during induction chemotherapy for acute myeloid leukaemia
Sep 17, 2013Eur J Haematol 2013; 92:90
Silzle Tobias, Glaser-Gallion Nicola, Hitz Felicitas
Pyrazinamide-induced sideroblastic anemia
Colucci G, Silzle T, Solenthaler M. Pyrazinamide-induced sideroblastic anemia. Am J Hematol 2011; 87:305.
Aug 4, 2011Pyrazinamide-induced sideroblastic anemia
Aug 4, 2011Am J Hematol 2011; 87:305
Colucci Giuseppe, Silzle Tobias, Solenthaler Max